HighMark Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

HighMark Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	38,595 +18,100	+88%	+$673K	0.48%	31
2026 Q1	$744K	Sell	20,495 -1,000	-5%	-$44.7K	0.3%	39
2025 Q4	$1M	Buy	21,495 +1,500	+8%	+$66.8K	0.41%	34
2025 Q3	$833K	Hold	19,995	–	–	0.37%	36
2025 Q2	$575K	Hold	19,995	–	–	0.28%	45
2025 Q1	$671K	Hold	19,995	–	–	0.4%	27
2024 Q4	$1.02M	Hold	19,995	–	–	0.59%	21
2024 Q3	$1.02M	Hold	19,995	–	–	0.56%	25
2024 Q2	$896K	Buy	19,995 +2,780	+16%	+$128K	0.54%	24
2024 Q1	$806K	Buy	17,215 +12,965	+305%	+$507K	0.5%	24
2023 Q4	$151K	Buy	+4,250	New	+$130K	0.11%	69

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighMark Wealth Management's CRNX Position: Q2 2026 in Review

HighMark Wealth Management increased its Crinetics Pharmaceuticals (CRNX) stake by 88% in Q2 2026, buying an estimated $673K and bringing the position to 38,595 shares worth $1.44M. The position accounts for 0.48% of the portfolio, ranked #31.

HighMark Wealth Management first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

HighMark Wealth Management held 38,595 shares of Crinetics Pharmaceuticals worth $1.44M as of Q2 2026.
HighMark Wealth Management bought 18,100 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $673K.
Crinetics Pharmaceuticals made up 0.48% of HighMark Wealth Management's portfolio in Q2 2026, its #31 holding.
HighMark Wealth Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.